GlassScriptPhysician profile
David Siegenberg
NPI 1578502563
$3,870.46
in general payments reported to CMS, 2019-2025
29 companies · $968 in 2025
The $968 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,220 · 2020: $374 · 2022: $22.00 · 2023: $314 · 2024: $973 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,145 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,144.62 |
| Education | $109.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $505.22 | 2019-2025 | Entyvio, Eohilia |
| Abbvie INC. | $498.15 | 2019-2025 | Skyrizi |
| Janssen Biotech, INC. | $451.48 | 2019-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $429.06 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.45 | 2019-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $231.80 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $206.57 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $171.40 | 2023-2025 | Sucraid, Sucraid |
| Allergan, INC. | $166.19 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $140.74 | 2023-2025 | Voquezna |
| Pfizer INC. | $131.23 | 2019-2025 | |
| Celgene Corporation | $124.39 | 2023 | Zeposia |
| Viiv Healthcare Company | $78.27 | 2025 | Apretude |
| Merck Sharp & Dohme LLC | $69.97 | 2019-2020 | |
| Braintree Laboratories, INC. | $65.43 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $62.28 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Genzyme Corporation | $47.75 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $44.99 | 2019-2024 | |
| Novo Nordisk INC | $35.53 | 2019 | |
| Shionogi INC | $21.54 | 2019 | |
| Nestle Healthcare Nutrition INC. | $19.79 | 2023 | |
| Janssen Pharmaceuticals, INC | $19.72 | 2025 | |
| Ucb, INC. | $18.58 | 2020 | |
| Alfasigma USA, INC. | $18.03 | 2020 | |
| Ferring Pharmaceuticals INC. | $17.07 | 2025 | Rebyota |
| Horizon Therapeutics Plc | $15.88 | 2019 | |
| Sanofi US Services INC. | $14.91 | 2025 | |
| Amarin Pharma, INC. | $13.92 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Siegenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.